Immunotherapy, gene editing advances extend to Type 1 Diabetes

(Seattle Children's) Advances in engineering T cells to treat cancer are paving the way for new immunotherapies targeted at autoimmune diseases, including type 1 diabetes. Now, researchers are also investigating therapies that reprogram T cells to 'turn down' an immune response, which may hold promise for curing type 1 diabetes, as well as a number of diseases where overactive T cells attack a person's healthy cells and organs.